GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Cash Ratio

Transcenta Holding (HKSE:06628) Cash Ratio : 0.99 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Transcenta Holding's Cash Ratio for the quarter that ended in Dec. 2023 was 0.99.

Transcenta Holding has a Cash Ratio of 0.99. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Transcenta Holding's Cash Ratio or its related term are showing as below:

HKSE:06628' s Cash Ratio Range Over the Past 10 Years
Min: 0.99   Med: 2.87   Max: 4.18
Current: 0.99

During the past 5 years, Transcenta Holding's highest Cash Ratio was 4.18. The lowest was 0.99. And the median was 2.87.

HKSE:06628's Cash Ratio is ranked worse than
72.81% of 1508 companies
in the Biotechnology industry
Industry Median: 2.955 vs HKSE:06628: 0.99

Transcenta Holding Cash Ratio Historical Data

The historical data trend for Transcenta Holding's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Cash Ratio Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
3.05 4.18 2.87 1.63 0.99

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only 2.87 2.21 1.63 1.40 0.99

Competitive Comparison of Transcenta Holding's Cash Ratio

For the Biotechnology subindustry, Transcenta Holding's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Cash Ratio falls into.



Transcenta Holding Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Transcenta Holding's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=597.232/606.273
=0.99

Transcenta Holding's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=597.232/606.273
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transcenta Holding  (HKSE:06628) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Transcenta Holding Cash Ratio Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding (HKSE:06628) Business Description

Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines